As for the role of IL-18 in predicting patients’ response to immunotherapy, it was shown that patients with non-small cell lung cancer who respond to treatment had lower levels of IL-18 compared to non-responders [164], which contrasts with other studies in the same tumor type [140,141]. This evidence concerns the gene IL18 and neoplasm.